Is cabozantinib effective in patients with advanced lung cancer? Use cycle and life span extension

Cabozantinib is an oral multi-target tyrosine kinase inhibitor that mainly targets VEGFR, MET, AXL and other signaling pathways closely related to tumor growth and metastasis. Although it was originally approved for renal cell carcinoma and hepatocellular carcinoma, in recent years more and more studies have shown that cabozantinib also shows certain therapeutic potential in certain types of non-small cell lung cancer (NSCLC), especially in patients with MET gene abnormalities or ALK inhibitor resistance.

Cabozantinib is expected to provide clinical benefit for patients with advanced non-small cell lung cancer, particularly those with MET amplification, exon 14 skipping mutations, or elevated AXL expression. Some studies and small clinical trials have shown that cabozantinib can produce tumor shrinkage and disease control in such patients. In terms of combined use, cabozantinib is also expected to be combined with immune checkpoint inhibitors such as atezolizumab to improve the therapeutic response to advanced patients.

The period of use of cabozantinib is not fixed and is usually adjusted based on the patient's tolerance to the drug and disease control. In most cases, cabozantinib can be continued for several months or even more than a year without serious side effects and disease progression. During treatment, blood pressure, liver function, electrolytes, and possible side effects such as hand-foot syndrome need to be closely monitored, and the dosage should be adjusted or medication suspended in a timely manner.

In terms of survival, although the specific extension time varies greatly between individuals, for patients with advanced lung cancer who have failed previous treatments or lack other treatment options, the addition of cabozantinib is expected to extend progression-free survival (PFS) by several months, and even extend overall survival (OS) in some groups. Although more large-scale randomized controlled studies are still needed to further confirm its exact positioning in the field of lung cancer, cabozantinib undoubtedly provides a new treatment option for some patients with advanced lung cancer.

Reference:https://en.wikipedia.org/wiki/Cabozantinib